Apimeds Pharmaceuticals US
Matawan, New Jersey, United States · Biopharma, Biotechnology, Health Care
Apimeds is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered honeybee venom-based toxin. They are focused on creating potential treatments for osteoarthritis knee pain. The company aims to offer solutions for patients who don't respond adequately to standard non-pharmacologic therapies. Apimeds is dedicated to advancing innovative therapeutic options.
Key facts
- Headquarters
- Matawan, New Jersey, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (APUS)
- Website
- www.apimedsus.com
- Company page
Recent activity at Apimeds Pharmaceuticals US
- : Apimeds Pharmaceuticals US names Sungjoon Chae Co-Chief Executive Officer
- : Apimeds Subsidiary Enters Two-Year Agreement with BlockAssure (date Fundz recorded it)
- : Apimeds Pharmaceuticals Appoints Eric Sherb as Chief Financial Officer
- : Apimeds Pharmaceuticals Enters into Assignment Agreement with FreeT Inc. (date Fundz recorded it)
- : SEC 8-K (8.01):
- : SEC 8-K (5.02): On September 29, 2026, Erick Frim resigned as the Interim Chief Financial Officer of Apimeds Pharmaceuticals US, Inc., effective immediately. His resignation was not due to any disagreements with the company regarding its operations or policies. Following this, on September 30, 2026, the Board of Directors appointed Eric Sherb as the new Chief Financial Officer, with the appointment taking effect on October 1, 2026. This transition in leadership may have strategic implications for the company's financial management as it approaches upcoming financial reporting periods.
- : SEC 8-K (8.01):
- : SEC 8-K (1.01): On September 10, 2026, Apimeds Pharmaceuticals US, Inc. and MindWave Innovations Inc. entered into the First Amendment to a Confidential Settlement and Mutual Release Agreement. This amendment modifies a prior settlement agreement dated April 24, 2026, involving multiple parties, including Lokahi Therapeutics, Erik Emerson, FreeT Inc. (formerly Inscobee Inc.), and Apimeds Inc. Key aspects of the amendment are not specified, but it indicates ongoing negotiations and adjustments related to prior arrangements. The strategic implications could involve resolving disputes related to contractual obligations, enhancing partnerships, or mitigating liabilities. The event reflects the company's proactive management of its legal agreements and potential impact on business operations.
- : SEC 8-K (1.01): On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement with FreeT Inc. pursuant to which FreeT irrevocably assigned its rights related to Apitox to Apimeds. These rights were originally part of an agreement established in 2015 between FreeT's predecessor, CNP Roen Co., Ltd., and the current company. This strategic move grants Apimeds full ownership of key Apitox-related assets which may enhance its product offerings in the pharmaceutical market. The transaction marks a significant collaboration in the field of Apitox research and development, thereby expanding Apimeds' operational scope.
- : SEC 8-K (8.01): On August 5, 2026, Apimeds Pharmaceuticals US, Inc. appointed Dr. Christopher Kim as its Chief Scientific Officer, effective immediately. Dr. Kim will oversee the scientific, clinical, and regulatory development of the Company's APITOX program, leveraging his extensive expertise to strengthen leadership continuity. This appointment is strategically important as it aligns with the Company's long-term development goals for APITOX, enhancing its capability to navigate regulatory processes and move towards commercialization. Dr. Kim's background in the program positions him to accelerate progress in obtaining necessary regulatory approvals.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Leadership
- Erik Emerson, CEO Apimeds US
- Sungjoon Chae, Co-Chief Executive Officer
- Erick Frim, Chief Financial Officer
- Eric Sherb, Chief Financial Officer
- Christopher Kim, Chairman and CMO
Verified email and direct lines for Apimeds Pharmaceuticals US’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Apimeds Pharmaceuticals US files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Apimeds Pharmaceuticals US
- Abivax · Biopharma, Biotechnology, Health Care, Therapeutics
- AbSci Corp · Biopharma, Biotechnology, Health Care, Therapeutics
- Milestone Pharmaceuticals · Biopharma, Biotechnology, Health Care, Therapeutics
- Morphic Holding · Biopharma, Biotechnology, Health Care, Therapeutics
- Estrella Immunopharma · Biopharma, Biotechnology, Health Care, Therapeutics
About Apimeds Pharmaceuticals US: questions and answers
What does Apimeds Pharmaceuticals US do?
Apimeds is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered honeybee venom-based toxin. They are focused on creating potential treatments for osteoarthritis knee pain. The company aims to offer solutions for patients who don't respond adequately to standard non-pharmacologic therapies. Apimeds is dedicated to advancing innovative therapeutic options.
Where is Apimeds Pharmaceuticals US headquartered?
Apimeds Pharmaceuticals US is headquartered in Matawan, New Jersey, United States.
Who leads Apimeds Pharmaceuticals US?
Erik Emerson is a CEO Apimeds US at Apimeds Pharmaceuticals US.
What is the latest news on Apimeds Pharmaceuticals US?
On Nov 6, 2026, Apimeds Pharmaceuticals US names Sungjoon Chae Co-Chief Executive Officer
Is Apimeds Pharmaceuticals US a public company?
Yes. Apimeds Pharmaceuticals US is publicly traded under the ticker APUS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy